Attovia Therapeutics, Inc. (ATTO)
| Market Cap | 631.36M |
| Revenue (ttm) | 1.80M |
| Net Income | -70.11M |
| EPS | -17.01 |
| Shares Out | 45.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 312,938 |
| Open | 14.36 |
| Previous Close | 14.50 |
| Day's Range | 13.53 - 14.75 |
| 52-Week Range | 12.94 - 28.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 42.20 (+205.13%) |
| Earnings Date | Sep 2, 2026 |
About ATTO
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobuli... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ATTO stock is "Strong Buy." The 12-month stock price target is $42.2, which is an increase of 205.13% from the latest price.
News
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for ...
Attovia Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The session highlighted rapid progress in developing modular nanobody-based biologics for immune-mediated diseases, with ATTO-1310 showing strong early efficacy and safety in chronic itch. Upcoming phase II trials target large unmet needs, while the pipeline expands into bispecific and trispecific assets, all supported by a robust financial position.
Attovia Therapeutics Slides: Corporate presentation
Attovia Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 7, 2026.
Attovia Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation bio...
Attovia reports Q2 EPS ($4.88), consensus ($4.61)
“Following the successful completion of our upsized IPO, Attovia (ATTO) enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near-term value-creatin...
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026
Attovia Therapeutics Quarterly report: Q2 2026
Attovia Therapeutics has published its Q2 2026 quarterly earnings report on September 2, 2026.
Attovia Therapeutics Earnings release: Q2 2026
Attovia Therapeutics released its Q2 2026 earnings on September 2, 2026, summarizing the period's financial results.
Attovia initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Attovia (ATTO) with an Outperform rating and $45 price target
Attovia initiated with an Outperform at Leerink
Leerink initiated coverage of Attovia (ATTO) with an Outperform rating and $52 price target
Attovia initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz initiated coverage of Attovia (ATTO) with a Buy rating and $30 price target The firm says the company has a “partially derisked” opportunity across large chronic…
Attovia initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Attovia (ATTO) with an Overweight rating and $39 price target The company’s focus on “de-risked targets” positions it path to blockbuster opportunities in chronic ...
Attovia initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Attovia (ATTO) with an Outperform rating and $45 price target The firm believes the company’s Attobody platform, which designs biologics against validated targets, wi...
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for i...
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, ...
Attovia opens at $21.00, IPO priced at $17.00
Attovia (ATTO) priced 17M shares at $17.00. The deal size was increased to 17M shares of common stock from 12.5M shares. The deal priced at the top of the $15.00-$17.00…
Attovia indicated to open at $20, IPO priced at $17
11:43 EDT Attovia (ATTO) indicated to open at $20, IPO priced at $17
Attovia indicated to open at $24, IPO priced at $17
Attovia (ATTO) priced 17M shares at $17.00. The deal size was increased to 17M shares of common stock from 12.5M shares. The deal priced at the top of the $15.00-$17.00…
Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering
SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for i...
Attovia Therapeutics Registration statement: Registration filing
Attovia Therapeutics filed a registration statement on August 4, 2026, providing details about a securities offering with the SEC.
Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
Biopharmaceutical company Attovia Therapeutics said on Tuesday it was targeting a valuation of $731.5 million in its upsized initial public offering, signaling strong demand for biopharma listings.
Attovia Therapeutics Registration statement: Registration filing
Attovia Therapeutics filed a registration statement on July 29, 2026, providing details about a securities offering with the SEC.
Attovia Therapeutics Appoints John W. Smither to Board of Directors
Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sector Mr. Smither brings extensive public company board and audit committee experience in the bio...
Biopharmaceutical company Attovia Therapeutics files for US IPO
Biopharmaceutical company Attovia Therapeutics on Tuesday filed for an initial public offering in the United States.
Attovia Therapeutics
Attovia Therapeutics has filed to go public with an IPO on the NASDAQ